Navigation Links
Fenwal Statement Regarding Patent Litigation
Date:6/4/2009

Company plans appeal and uninterrupted supply for customers

LAKE ZURICH, Ill., June 4 /PRNewswire/ -- Fenwal Inc., a global leader focused on improving blood collection, safety and availability for patient care, said it will appeal the decision by a Boston court in a patent lawsuit brought by Haemonetics Corporation in 2005. Fenwal believes it has strong grounds for a successful appeal.

In conjunction with this litigation, Judge Nathaniel M. Gorton of the United States District Court for the District of Massachusetts decided on Monday, June 1, 2009, that beginning December 1, 2010 (approximately 18 months from now), Fenwal will be enjoined from selling current ALYX(R) disposable kits that contain an infringing component. The order, which also specifies royalties, applies only to these disposable kits and not to the ALYX(R) system itself, nor to any future ALYX(R) products that do not contain the infringing component.

Fenwal will appeal the final judgment when entered. To assure continued supply for customers, Fenwal also will modify the component found to infringe. The company plans to introduce the modified kit, which is currently in development, before the end of 2009, well in advance of the injunction date. This kit will be fully compatible with the existing ALYX(R) system. No changes will be required to the ALYX(R) system itself. Fenwal expects no procedural changes will be required, nor new validation will be recommended for customers.

Fenwal is taking these actions to assure blood centers are able to maintain an adequate blood supply for patients through uninterrupted access to Fenwal's blood-separation technology. Blood centers around the world rely on the ALYX(R) system to collect red cells needed by patients who require blood transfusions.

"We are committed to working closely with customers and assuring their operations are not disrupted as we continue to work through the next steps in resolving this litigation," said Dean Gregory, Fenwal senior vice president of Commercial Operations. "We have believed from the beginning that the claims against Fenwal have no merit and we will defend our position on behalf of our customers and employees. We also are continuing to develop new innovations for the ALYX(R) system that further improve the donor experience and help blood centers fulfill their mission with greater safety, quality and productivity."

Fenwal developed the ALYX(R) system independent of the Haemonetics patent. Haemonetics, which purchased the patent from a third-party inventor, has never incorporated the technology into any commercial product.

About Fenwal

Fenwal Inc. is a global medical technology company focused on improving blood collection, separation, safety and availability for patient care. Fenwal became an independent company in 2007, but its roots go back to 1949 with the founding of Fenwal Laboratories. Fenwal developed the first flexible, disposable container for blood collection, eliminating complications associated with glass containers and allowing blood to be separated into therapeutic components. Today, the company's products and advanced collection and separation technologies are used throughout the world to help ensure a safe and available supply of lifesaving blood and blood products. Fenwal Inc. is based in Lake Zurich, Illinois. For more information, please visit www.fenwalinc.com.


'/>"/>
SOURCE Fenwal Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Fenwal Names 2008 Inductees for Blood Donation Hall of Fame
2. Fenwal Signs Development, Distribution and Licensing Agreement With Data Innovations, Inc.
3. AABB and Fenwal Sponsor Third Annual Blood Collectors Week
4. MHPA, Leading Association Representing Medicaid Health Plans, Issues Statement on Proposed California SCHIP Elimination
5. Statement of the Attorney General on Murder of Doctor George Tiller
6. Providence Service Corporation Rebuts False and Misleading Statements Contained in Proxy Statement Filed by the Avalon Group
7. Statement of National Business Group on Health
8. Statement by American Legacy Foundation(R): Findings of Decades of Massive Fraud by Tobacco Industry Upheld in U.S. Court of Appeals
9. Major Physician Group Issues Statement in Support of Physician/Industry Relationships
10. Statement from CCF Against CDC Nominee Thomas Frieden
11. Amylin Issues Statement Regarding Open Letter From Icahn
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/2/2016)... NV (PRWEB) , ... May 02, 2016 , ... ... Pharmacy Times, has announced a new Specialty Pharmacy Patient Satisfaction Award that will ... based on the quarterly results from Zitter Health Insights’ Specialty Pharmacy Patient Satisfaction ...
(Date:5/2/2016)... ... May 02, 2016 , ... The 2016 World Ultimate & Guts Championship (WUGC) Mixed roster was ... made the cut. The WUGC is being held in London, England this year from June ... the men’s division, another gold in the women’s masters division, and a silver in the ...
(Date:5/2/2016)... ... , ... Pregnancy Awareness Month offers a great time to get familiar with ... are ready to have a baby, it’s best to get started before age becomes ... Personal Conception & Pregnancy Organizer, written for women who plan on becoming pregnant to ...
(Date:5/2/2016)... (PRWEB) , ... May 02, 2016 , ... ... division of Permobil, recently completed two groundbreaking studies that determined that the adjustability ... – are critical in the prevention of pressure injuries, which are now referred ...
(Date:5/2/2016)... Washington, DC (PRWEB) , ... May 02, 2016 , ... ... “ How CMS’s Medicare Part B Payment Model Could Transform the Pharma Landscape .” ... an eye on reducing its spend on provider-administered drugs while preserving care provided to ...
Breaking Medicine News(10 mins):
(Date:4/29/2016)... 29, 2016 ReportsnReports.com adds ... market research report that provides an overview of ... at various stages, therapeutics assessment by drug target, ... and molecule type, along with latest updates, and ... key players involved in the therapeutic development for ...
(Date:4/29/2016)... 2016 Glycotope GmbH, a clinical-stage ... the appointment of Dr. Alfredo Zurlo as ... oncologist with many years clinical experience and a proven ... last role was at Mologen AG where he was ... Previously Dr. Zurlo held various positions at F Hoffmann ...
(Date:4/28/2016)... , April 28, 2016  While Abbott,s ... complement the company,s valve repair and stent business, ... also places Abbott more firmly into patient monitoring.  ... the fastest growing device areas, with double-digit growth ... recent report,  Advanced Remote Patient Monitoring ...
Breaking Medicine Technology: